Terms: = Leukemia AND CDKN1B, CDKN4, 1027, ENSG00000111276, MEN4, P27KIP1, P46527, MEN1B, KIP1 AND Prognosis
34 results:
1. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid leukemia and High-risk Myelodysplastic Syndrome].
Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
[TBL] [Abstract] [Full Text] [Related]
2. MicroRNA profiling of paediatric AML with
Leoncini PP; Vitullo P; Reddel S; Tocco V; Paganelli V; Stocchi F; Mariggiò E; Massa M; Nigita G; Veneziano D; Fadda P; Scarpa M; Pigazzi M; Bertaina A; Rota R; Pagliara D; Merli P
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36321792
[TBL] [Abstract] [Full Text] [Related]
3. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract] [Full Text] [Related]
4. Antitumor effect of baicalin from the Scutellaria baicalensis radix extract in B-acute lymphoblastic leukemia with different chromosomal rearrangements.
Orzechowska BU; Wróbel G; Turlej E; Jatczak B; Sochocka M; Chaber R
Int Immunopharmacol; 2020 Feb; 79():106114. PubMed ID: 31881375
[TBL] [Abstract] [Full Text] [Related]
5. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah V; Sherborne AL; Walker BA; Johnson DC; Boyle EM; Ellis S; Begum DB; Proszek PZ; Jones JR; Pawlyn C; Savola S; Jenner MW; Drayson MT; Owen RG; Houlston RS; Cairns DA; Gregory WM; Cook G; Davies FE; Jackson GH; Morgan GJ; Kaiser MF
Leukemia; 2018 Jan; 32(1):102-110. PubMed ID: 28584253
[TBL] [Abstract] [Full Text] [Related]
7. TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway.
Wang SY; Gao K; Deng DL; Cai JJ; Xiao ZY; He LQ; Jiao HL; Ye YP; Yang RW; Li TT; Liang L; Liao WT; Ding YQ
Oncotarget; 2016 Jan; 7(3):2878-88. PubMed ID: 26701208
[TBL] [Abstract] [Full Text] [Related]
8. Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.
Bokemeyer A; Eckert C; Meyr F; Koerner G; von Stackelberg A; Ullmann R; Türkmen S; Henze G; Seeger K
Haematologica; 2014 Apr; 99(4):706-14. PubMed ID: 24241490
[TBL] [Abstract] [Full Text] [Related]
9. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells.
Kustikova OS; Schwarzer A; Stahlhut M; Brugman MH; Neumann T; Yang M; Li Z; Schambach A; Heinz N; Gerdes S; Roeder I; Ha TC; Steinemann D; Schlegelberger B; Baum C
Leukemia; 2013 Apr; 27(5):1127-38. PubMed ID: 23212151
[TBL] [Abstract] [Full Text] [Related]
10. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).
Wang X; Gocek E; Novik V; Harrison JS; Danilenko M; Studzinski GP
Cell Cycle; 2010 Nov; 9(22):4542-51. PubMed ID: 21084834
[TBL] [Abstract] [Full Text] [Related]
12. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221.
Kotani A; Ha D; Hsieh J; Rao PK; Schotte D; den Boer ML; Armstrong SA; Lodish HF
Blood; 2009 Nov; 114(19):4169-78. PubMed ID: 19749093
[TBL] [Abstract] [Full Text] [Related]
13. [Expression of P27(kip1) and cyclin G in patients with acute leukemia and its correlation].
Chen HY; Lin DH; Luo LQ; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):847-51. PubMed ID: 19698214
[TBL] [Abstract] [Full Text] [Related]
14. SKP2 siRNA inhibits the degradation of p27kip1 and down-regulates the expression of MRP in HL-60/A cells.
Xiao J; Yin S; Li Y; Xie S; Nie D; Ma L; Wang X; Wu Y; Feng J
Acta Biochim Biophys Sin (Shanghai); 2009 Aug; 41(8):699-708. PubMed ID: 19657571
[TBL] [Abstract] [Full Text] [Related]
15. p27kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
Bertagnolli MM; Warren RS; Niedzwiecki D; Mueller E; Compton CC; Redston M; Hall M; Hahn HP; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Loda M
Clin Cancer Res; 2009 Mar; 15(6):2116-22. PubMed ID: 19276255
[TBL] [Abstract] [Full Text] [Related]
16. High intracellular content of cyclin-dependent kinase inhibitor p27(kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
[TBL] [Abstract] [Full Text] [Related]
17. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease.
Jardin F; Callanan M; Penther D; Ruminy P; Troussard X; Kerckaert JP; Figeac M; Parmentier F; Rainville V; Vaida I; Bertrand P; Duval AB; Picquenot JM; Chaperot L; Marolleau JP; Plumas J; Tilly H; Bastard C
Leukemia; 2009 Apr; 23(4):698-707. PubMed ID: 19158833
[TBL] [Abstract] [Full Text] [Related]
18. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.
Wang Z; Smith KS; Murphy M; Piloto O; Somervaille TC; Cleary ML
Nature; 2008 Oct; 455(7217):1205-9. PubMed ID: 18806775
[TBL] [Abstract] [Full Text] [Related]
19. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.
Datta A; Bellon M; Sinha-Datta U; Bazarbachi A; Lepelletier Y; Canioni D; Waldmann TA; Hermine O; Nicot C
Blood; 2006 Aug; 108(3):1021-9. PubMed ID: 16569765
[TBL] [Abstract] [Full Text] [Related]
20. Mutational analysis of the cell cycle inhibitor kip1/p27 in childhood leukemia.
Markaki EA; Stiakaki E; Zafiropoulos A; Arvanitis DA; Katzilakis N; Dimitriou H; Spandidos DA; Kalmanti M
Pediatr Blood Cancer; 2006 Jul; 47(1):14-21. PubMed ID: 16526056
[TBL] [Abstract] [Full Text] [Related]
[Next]
